Simonetta M Leto
Overview
Explore the profile of Simonetta M Leto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leto S, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, et al.
Nat Commun
. 2024 Aug;
15(1):7495.
PMID: 39209908
The breadth and depth at which cancer models are interrogated contribute to the successful clinical translation of drug discovery efforts. In colorectal cancer (CRC), model availability is limited by a...
2.
Leto S, Ferri M, Sassi F, Zanella E, Cottino F, Vurchio V, et al.
Clin Cancer Res
. 2023 Jan;
29(6):1102-1113.
PMID: 36622698
Purpose: Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor...
3.
Jaaks P, Coker E, Vis D, Edwards O, Carpenter E, Leto S, et al.
Nature
. 2022 Feb;
603(7899):166-173.
PMID: 35197630
Combinations of anti-cancer drugs can overcome resistance and provide new treatments. The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations...
4.
Leto S, Sassi F, Catalano I, Torri V, Migliardi G, Zanella E, et al.
Clin Cancer Res
. 2015 Aug;
21(24):5519-31.
PMID: 26296355
Purpose: Preclinical studies in HER2-amplified gastrointestinal cancer models have shown that cotargeting HER2 with a monoclonal antibody and a small molecule is superior to monotherapy with either inhibitor, but the...
5.
Kavuri S, Jain N, Galimi F, Cottino F, Leto S, Migliardi G, et al.
Cancer Discov
. 2015 Aug;
5(8):832-41.
PMID: 26243863
Unlabelled: The Cancer Genome Atlas project identified HER2 somatic mutations and gene amplification in 7% of patients with colorectal cancer. Introduction of the HER2 mutations S310F, L755S, V777L, V842I, and...
6.
Zanella E, Galimi F, Sassi F, Migliardi G, Cottino F, Leto S, et al.
Sci Transl Med
. 2015 Jan;
7(272):272ra12.
PMID: 25632036
Among patients with colorectal cancer who benefit from therapy targeted to the epidermal growth factor receptor (EGFR), stable disease (SD) occurs more frequently than massive regressions. Exploring the mechanisms of...
7.
Leto S, Trusolino L
J Mol Med (Berl)
. 2014 May;
92(7):709-22.
PMID: 24811491
Only approximately 10% of genetically unselected patients with chemorefractory metastatic colorectal cancer experience tumor regression when treated with the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab ("primary" or...